JP2013540445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540445A5 JP2013540445A5 JP2013534008A JP2013534008A JP2013540445A5 JP 2013540445 A5 JP2013540445 A5 JP 2013540445A5 JP 2013534008 A JP2013534008 A JP 2013534008A JP 2013534008 A JP2013534008 A JP 2013534008A JP 2013540445 A5 JP2013540445 A5 JP 2013540445A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- promoter
- peptide
- signal protein
- recombinant cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 7
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 7
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 claims description 6
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 6
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims description 6
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 claims description 6
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims description 6
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 6
- 210000002660 insulin-secreting cell Anatomy 0.000 claims description 6
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 230000008672 reprogramming Effects 0.000 claims description 5
- 101100281124 Aquifex aeolicus (strain VF5) flaA gene Proteins 0.000 claims description 4
- 241000305071 Enterobacterales Species 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 101150038062 fliC gene Proteins 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 108091026890 Coding region Proteins 0.000 claims 12
- 101000777158 Danio rerio Ubiquitin carboxyl-terminal hydrolase 45 Proteins 0.000 claims 2
- 101000760243 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 45 Proteins 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 102100024718 Ubiquitin carboxyl-terminal hydrolase 45 Human genes 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 claims 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 208000031662 Noncommunicable disease Diseases 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 108091069196 IL-1 family Proteins 0.000 description 2
- 102000039996 IL-1 family Human genes 0.000 description 2
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108050003475 Neuregulin Proteins 0.000 description 2
- 102000014413 Neuregulin Human genes 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102100031942 Oncostatin-M Human genes 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- -1 TNFβ Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000007641 Trefoil Factors Human genes 0.000 description 2
- 108010007389 Trefoil Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011796 Cystitis interstitial Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020740 Hyperproteinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39361810P | 2010-10-15 | 2010-10-15 | |
| US61/393,618 | 2010-10-15 | ||
| US201161539121P | 2011-09-26 | 2011-09-26 | |
| US61/539,121 | 2011-09-26 | ||
| PCT/US2011/056174 WO2012051431A2 (en) | 2010-10-15 | 2011-10-13 | Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540445A JP2013540445A (ja) | 2013-11-07 |
| JP2013540445A5 true JP2013540445A5 (enExample) | 2014-12-04 |
| JP6033780B2 JP6033780B2 (ja) | 2016-11-30 |
Family
ID=45938977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534008A Active JP6033780B2 (ja) | 2010-10-15 | 2011-10-13 | 内分泌障害、胃腸障害または自己免疫障害を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9265842B2 (enExample) |
| EP (1) | EP2627770B1 (enExample) |
| JP (1) | JP6033780B2 (enExample) |
| KR (1) | KR20130097789A (enExample) |
| CN (1) | CN103429742A (enExample) |
| BR (1) | BR112013008957A2 (enExample) |
| CA (1) | CA2814698A1 (enExample) |
| WO (1) | WO2012051431A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101998987A (zh) * | 2008-04-09 | 2011-03-30 | 康奈尔大学 | 在哺乳动物宿主内作为信号介质的共生菌 |
| JP6456853B2 (ja) * | 2013-03-13 | 2019-01-23 | ビオクリネ エービー | 糖尿病を治療および／または発症を制限するための方法 |
| WO2014176311A1 (en) | 2013-04-23 | 2014-10-30 | President And Fellows Of Harvard College | Genetic reprogramming of bacterial biofilms |
| WO2016035820A1 (ja) * | 2014-09-02 | 2016-03-10 | 学校法人東京理科大学 | 中枢作用性ペプチド誘導体及び医薬組成物 |
| JP6916524B2 (ja) | 2015-04-06 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 機能的タンパク質配列をディスプレイする生合成アミロイドに基づく材料 |
| GB2545395A (en) * | 2015-11-27 | 2017-06-21 | The Inst Of Food Res | Engineered lactococcus lactis producing biologically active GLP-1 |
| US11098133B2 (en) | 2016-05-19 | 2021-08-24 | President And Fellows Of Harvard College | Methods of making gels and films using curli nanofibers |
| US20190282710A1 (en) * | 2016-07-18 | 2019-09-19 | Eth Zurich | B-cell-mimetic cells |
| US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
| AU2017357072A1 (en) * | 2016-11-14 | 2019-05-30 | Memorial Sloan-Kettering Cancer Center | Stem cell derived schwann cells |
| RU2753193C2 (ru) * | 2016-12-09 | 2021-08-12 | Зилэнд Фарма А/С | Ацилированные двойные агонисты glp-1/glp-2 |
| US10925930B2 (en) * | 2017-02-27 | 2021-02-23 | Urigen N.A. | Treatment of lower urinary tract epithelium with glucagon like peptide 2 |
| US20200230118A1 (en) * | 2017-04-11 | 2020-07-23 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Use of berberine or active metabolite thereof in preparation of drug for preventing and/or treating phenylketonuria |
| EP3612198A4 (en) * | 2017-04-17 | 2021-01-13 | The Regents of the University of California | MODIFIED COMMENSAL BACTERIA AND METHODS OF USE |
| WO2019050898A1 (en) * | 2017-09-05 | 2019-03-14 | Azitra Inc | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE |
| CN108060195A (zh) * | 2017-12-29 | 2018-05-22 | 广东唯泰生物科技有限公司 | 一种发酵生产重组胰高血糖素样肽-1蛋白的方法 |
| KR101915951B1 (ko) * | 2018-01-09 | 2018-11-07 | 주식회사 쎌바이오텍 | P8 단백질을 발현 및 분비하는 위장관 질환 치료 약물 전달용 미생물 및 그를 포함하는 위장관 질환 예방 또는 치료용 약제학적 조성물 |
| CN110157801B (zh) * | 2018-02-12 | 2021-03-09 | 清华大学 | 一种组合标志物及其在制备胃癌发生风险预测试剂盒中的应用及其测定系统和方法 |
| CN110721203A (zh) * | 2018-07-17 | 2020-01-24 | 深圳爱米基因科技有限责任公司 | 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 |
| CN110172433B (zh) * | 2019-05-12 | 2021-07-30 | 华中农业大学 | 一种产猪表皮生长因子的重组枯草芽孢杆菌工程菌及应用 |
| CN114426942B (zh) * | 2022-01-25 | 2024-07-09 | 中国科学院动物研究所 | 一种重组乳酸乳球菌、微胶囊及其应用 |
| CN114606253B (zh) * | 2022-03-14 | 2024-03-26 | 浙江工业大学 | 一种无外源氨基酸作用下高产l-甲硫氨酸的重组大肠杆菌及其应用 |
| CN116333954B (zh) * | 2022-11-02 | 2025-12-05 | 南昌大学 | 一种分泌glp-1的基因工程菌及其制备方法和应用 |
| CN119351440B (zh) * | 2024-12-25 | 2025-04-25 | 浙江大学衢州研究院 | 表达glp-1的重组载体、重组酵母及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019733B2 (ja) | 1977-06-10 | 1985-05-17 | 科研製薬株式会社 | 蛋白質性活性物質 |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| WO1997029180A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US8778899B2 (en) * | 1999-06-01 | 2014-07-15 | Sarah Ferber | Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| PT1429802E (pt) | 2001-09-28 | 2013-01-24 | Tntgamble Inc | Sistema de entrega para componente biológico |
| CN100480374C (zh) | 2001-09-28 | 2009-04-22 | 中国科学院上海生命科学研究院 | 制备重组人类胰高血糖素肽－1氨基酸7－37肽段的方法 |
| CU23229A1 (es) | 2002-05-10 | 2007-09-26 | Ct Ingenieria Genetica Biotech | ANTAGONISTA QUIMéRICO ANTH1 |
| US7374930B2 (en) | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
| WO2005100544A2 (en) | 2004-04-12 | 2005-10-27 | The Trustees Of Princeton University | SMALL RNAs AND BACTERIAL STRAINS INVOLVED IN QUORUM SENSING |
| EP2390264A1 (en) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
| AU2007247137A1 (en) | 2006-05-02 | 2007-11-15 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
| RU2495129C2 (ru) * | 2007-01-12 | 2013-10-10 | Актогеникс Н.В. | ПРОМОТОРЫ Lactococcus И ИХ ПРИМЕНЕНИЕ: |
| EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
| EP2072556A1 (de) | 2007-12-17 | 2009-06-24 | Sika Technology AG | Verfahren zur Herstellung von hydroxyfunktionellen Polymeren, die hieraus gewinnbaren Isocyanatgruppen-endständigen Polyadditionsprodukte sowie deren Verwendung |
| CN101998987A (zh) * | 2008-04-09 | 2011-03-30 | 康奈尔大学 | 在哺乳动物宿主内作为信号介质的共生菌 |
| US8680051B2 (en) * | 2008-12-19 | 2014-03-25 | Qinghua Wang | Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds |
-
2011
- 2011-10-13 EP EP11833419.2A patent/EP2627770B1/en active Active
- 2011-10-13 CA CA2814698A patent/CA2814698A1/en not_active Abandoned
- 2011-10-13 BR BR112013008957A patent/BR112013008957A2/pt not_active IP Right Cessation
- 2011-10-13 US US13/879,501 patent/US9265842B2/en active Active
- 2011-10-13 WO PCT/US2011/056174 patent/WO2012051431A2/en not_active Ceased
- 2011-10-13 KR KR1020137012406A patent/KR20130097789A/ko not_active Ceased
- 2011-10-13 CN CN2011800602655A patent/CN103429742A/zh active Pending
- 2011-10-13 JP JP2013534008A patent/JP6033780B2/ja active Active
-
2016
- 2016-02-12 US US15/043,409 patent/US10076577B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540445A5 (enExample) | ||
| JP6033780B2 (ja) | 内分泌障害、胃腸障害または自己免疫障害を処置するための組成物および方法 | |
| EP3010530B1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| US20090111742A1 (en) | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes | |
| CN115947822B (zh) | 一种长效酰化胰岛素衍生物及其药物组合物和应用 | |
| Angeli et al. | Incretin-based therapies: can we achieve glycemic control and cardioprotection? | |
| CN111793126A (zh) | Glp-1类似物多肽的制备方法及在ⅱ型糖尿病中应用 | |
| ES2970116T3 (es) | Composición farmacéutica para tratar la sarcopenia agonista del receptor del péptido de tipo 1 similar al glucagón | |
| JP2008527988A5 (enExample) | ||
| Goldspink | Skeletal muscle as an artificial endocrine tissue | |
| US10113184B2 (en) | Microbe transformant for weight loss and lipid reduction, the method for constructing the transformant, and application thereof | |
| Mora et al. | Cardiovascular outcome trials of the incretin-based therapies: what do we know so far? | |
| JP2015524432A5 (enExample) | ||
| CN103804488A (zh) | 使用食品级乳酸菌生产和递送的胰高血糖素样肽(glp-1和glp-2)及其制备方法 | |
| Manta et al. | Sulfonylureas as treatment choice in Diabetes Mellitus: Where are we now | |
| WO2025087301A1 (en) | Circular rna encoding glp-1 and the use thereof | |
| Kolawole et al. | IFEMED | |
| WO2019036859A1 (zh) | 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途 | |
| KUMAR | GLP-1: A HORMONE TO TREAT DIABETES | |
| KR20230160188A (ko) | 락토바실러스 퍼멘텀 균주 및 대사조절제를 포함하는 병용 요법을 이용한 대사질환 예방 또는 치료용 조성물 | |
| John et al. | Short term use of octreotide in acromegaly | |
| WO2024051787A1 (zh) | 一种长效酰化胰岛素衍生物及其应用 | |
| KR20250133616A (ko) | 인터루킨-7 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주 | |
| Jørgensen et al. | Is somatostatin pivotal in intra-islet communication?—A knock down study | |
| RU2018112484A (ru) | Модифицированные грамположительные бактерии и их применение |